UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 12, 2026 |
CytoDyn, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
000-49908 |
83-1887078 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
1111 MAIN STREET, SUITE 660 |
|
VANCOUVER, Washington |
|
98660 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 360 980-8524 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered
|
None |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) and (e) On November 17, 2026, the Company entered into an agreement with Lauren Wilcoxen, Ph.D. (“Dr. Wilcoxen”), under which Dr. Wilcoxen will serve as the Company’s Chief Operating Officer (“COO”) and Head of Regulatory Affairs, effective November 20, 2026 (the “Employment Agreement”). The Company’s Board of Directors (the “Board”) approved the election of Dr. Wilcoxen as the Company’s COO on November 12, 2026.
Dr. Wilcoxen, age 40, brings extensive experience in regulatory affairs, clinical development and biotechnology operations, including a track record of advancing oncology programs through key regulatory milestones. Over the past several years, Dr. Wilcoxen has provided regulatory consulting and operational support services to a variety of public and private biotechnology and pharmaceutical companies. Most recently, from August 2026 to November 2026, she served as Senior Vice President, Regulatory Affairs of Xilio Therapeutics, Inc. (NASDAQ: XLO), a publicly traded clinical-stage biotechnology company. From June 2025 to August 2026, Dr. Wilcoxen provided independent regulatory consulting services to oncology biotechnology companies through Clarivance Bio, LLC. From May 2022 to October 2025, she served as Senior Vice President, Product Development and Regulatory Affairs of Checkpoint Therapeutics, Inc. (formerly NASDAQ: CKPT), which was a publicly traded clinical-stage biotechnology company until its acquisition by Sun Pharmaceutical Industries, Inc. From June 2020 to September 2022, she served as Vice President, Regulatory Affairs of Istari Oncology, Inc., a private clinical-stage biotechnology company.
There are no family relationships, as defined in Item 401 of Regulation S-K, between Dr. Wilcoxen and any of the Company’s other executive officers and directors. Other than the Employment Agreement, there is no arrangement or understanding between Dr. Wilcoxen and any other person pursuant to which she was appointed as COO of the Company. There are no transactions in which Dr. Wilcoxen has an interest requiring disclosure under Item 404(a) of Regulation S-K.
Dr. Wilcoxen’s initial compensation under the Employment Agreement, which was approved by the Board’s Compensation Committee (the “Committee”), includes the following: an initial annual base salary of $425,000, subject to periodic adjustment, eligibility to participate in the Company’s short- and long-term incentive plans in which other executive officers may participate, including a target annual bonus of 40% of her base salary earned for services during the fiscal year ending May 31, 2027; and an award of a nonqualified stock option to purchase 4,500,000 shares of the Company’s common stock under the Company’s Amended and Restated 2012 Equity Incentive Plan. The stock options will have an exercise price equal to the closing price of the common stock on the grant date and will vest over a four-year period beginning on the grant date. Under the Employment Agreement, either party may terminate Dr. Wilcoxen’s employment with the Company at any time, with or without cause, and with or without advance notice. The Employment Agreement also provides for certain severance benefits. The foregoing description of the Employment Agreement is not complete and is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which is filed herewith as Exhibit 10.1.
Item 7.01 Regulation FD Disclosure.
A copy of the press release issued by the Company on November 17, 2026, announcing Dr. Wilcoxen’s appointment as the Company’s COO is furnished as Exhibit 99.1.
Item 9.01 Financial Statement and Exhibits.
(d) Exhibits.
|
|
|
|
|
|
|
|
|
Exhibit No. |
|
Description |
10.1 |
|
Employment Agreement between the Company and Lauren Wilcoxen, dated November 17, 2026 |
99.1 |
|
Press Release dated November 17, 2026** |
104 |
|
Cover Page Interactive Data File (formatted as inline XBRL) |
** Furnished, not filed.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
CYTODYN INC. |
|
|
|
|
Date: |
November 17, 2026 |
By: |
/s/ Tyler Blok |
|
|
|
Tyler Blok Chief Legal Officer |
Exhibit 99.1
CytoDyn Announces Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
VANCOUVER, Washington, November 17, 2026 – CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced Lauren Wilcoxen, Ph.D., as its new Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026.
Dr. Wilcoxen brings extensive experience in regulatory affairs, clinical development and biotechnology operations, including a track record of advancing oncology programs through key regulatory milestones. Most recently, she served as Senior Vice President of Regulatory Affairs at Xilio Therapeutics, Inc. (NASDAQ: XLO), a publicly traded clinical-stage biotechnology company. From May 2022 to October 2025, Dr. Wilcoxen helped lead a team that secured FDA approval of a novel checkpoint inhibitor for skin cancer while serving as Senior Vice President, Product Development and Regulatory Affairs of Checkpoint Therapeutics, Inc. (formerly, NASDAQ: CKPT), a publicly traded clinical-stage biotechnology company, until its acquisition by Sun Pharmaceutical Industries, Inc. in 2025. Over the past several years, she has also advised various public and private biotechnology and pharmaceutical companies on regulatory strategy, clinical development and operational execution, with a focus on navigating complex oncology development programs and coordinating cross-functional teams.
“Lauren's appointment comes at an important time for CytoDyn as we continue to advance our oncology development strategy and build on emerging findings from our CLOVER study,” said Robert E. Hoffman, Chief Executive Officer of CytoDyn. “Her extensive regulatory expertise, recent success working with the FDA's Division of Oncology, and firsthand knowledge of our clinical programs make her exceptionally well suited to help guide CLOVER through the completion of Phase 2 and shape our regulatory strategy for the next stages of leronlimab's development. We are pleased to welcome her to our executive leadership team.”
Dr. Wilcoxen has served as a consultant to CytoDyn over the past year, advising on key clinical decisions and gaining firsthand knowledge of the Company's clinical programs, including its Phase 2 CLOVER study evaluating leronlimab in metastatic colorectal cancer.
“Having worked closely with CytoDyn over the past year, I have developed a strong understanding of leronlimab's scientific rationale, the CLOVER study, and the opportunities ahead for the Company's oncology programs,” said Dr. Wilcoxen. “I am encouraged by the emerging clinical findings and look forward to working with the team to translate these insights into a clear, rigorous regulatory and clinical development strategy. Our priority will be to work closely with the FDA to define a clear regulatory strategy that supports leronlimab’s continued clinical development.”
Dr. Wilcoxen currently serves on the board of directors of two cancer nonprofits, the American Cancer Society and Caring Community Foundation, and was named one of the Top 50 Women Leaders in Healthcare by Women We Admire in January 2025. She also holds a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society, a Ph.D. in microbiology and immunology from The University of North Carolina at Chapel Hill, and a B.S. in biology from Mount Saint Mary’s University.
About CytoDyn
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements relating to, among other things, mechanism of action, clinical development programs, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.
Corporate Contact
CytoDyn Inc.
ir@cytodyn.com
Media Contacts
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com